Abstract Library

#4483 Metabolic parameters and visceral adiposity index in type 1 gastric neuroendocrine tumours: A single-centre cross-sectional study

Introduction: Studies have shown that the accumulation of visceral fat and the occurrence of metabolic syndrome (MetS) lead to disruptions in immune-metabolic crosstalk, contributing to the development and progression of autoimmune diseases and well-differentiated gastric neuroendocrine tumours (gNETs).

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen R, Wang Y, Wang Y,

Keywords: Type 1 gastric neuroendocrine tumour, Metabolic Syndrome, Visceral Adiposity Index,

#4283 Long-term efficacy and safety of peptide receptor radionuclide therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumour: Japanese phase I and phase I/II extension study

Introduction: PRRT with 177Lu-DOTATATE has been approved in Japan according to Japanese phase I and Phase I/II clinical trials. Primary end point of these clinical studies was safety and response rate, therefore, long-term efficacy and safety of PRRT for Japanese patients with NET are uncertain.

Conference:

Presenting Author: Ichikawa Y

Authors: Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A,

Keywords: Neuroendocrine tumour, Peptide receptor radionuclide therapy, Japanese patients,

#4043 Treatments, clinicopathological characteristics and prognosis in thymic neuroendocrine tumors (TNETs): With especial reference to Temozolomide (TMZ)-based chemotherapy

Introduction: Thymic neuroendocrine tumors (TNETs) are rare but aggressive malignant neoplasms that exhibit significant heterogeneity. However, there is a paucity of comprehensive clinical studies conducted to investigate the prognosis of TNETs.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Cui L, Chen X, Zheng J,

Keywords: thymic neuroendocrine tumor, treatment, prognosis, temozolomide,

#3982 Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study

Introduction: After the approval of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Japan (June 2021), its treatment experience is increasing, but limited data are available in Japanese patients with neuroendocrine neoplasm (NEN).

Conference:

Presenting Author:

Authors: Okamoto K, Hijioka S, Goto Y, Honma Y, Hirano H,

Keywords: PRRT, 177Lu-DOTATATE, Japanese cohort,

#3958 Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

Introduction: There are still many unclear issues regarding the treatment of non-functioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs).

Conference:

Presenting Author: Hijioka S

Authors: Hijioka S, Yamashige D, Esaki M, Honda G, Masui T,

Keywords: small pancreatic neuroendocrine neoplasm, tumor size, grading, treatment strategy, Japanese cohort,